It has been demonstrated that PPARG agonists, such as thiazolidinediones, enhance renal outcomes in diabetic nephropathy by increasing insulin sensitivity, lowering inflammation, and lowering albuminuria [73]. The gene discussed is INS; the disease is diabetic kidney disease.